Arvinas vs Protagonist Therapeutics
ARVN and PTGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARVN and PTGX compare
Protagonist Therapeutics is the larger company, worth 18 times as much as Arvinas ($9.4B against $514M).
On earnings, Arvinas is cheaper: it trades at 49.1× trailing earnings, against 141× for Protagonist Therapeutics.
Protagonist Therapeutics grew revenue faster over the last twelve months (34.8% versus −15.0% for Arvinas).
Protagonist Therapeutics keeps more of each dollar of sales as profit, with a net margin of 29.4% compared with 2.9% at Arvinas.
Protagonist Therapeutics scores higher on the StockData Score (12 against 8 for Arvinas), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARVN | PTGX |
|---|---|---|
| Size and price | ||
| Market cap | $514M | $9.4B |
| Share price | $7.86 | $144.85 |
| Change, 1 year | −18.0% | 88.9% |
| Change, 5 years | −91.4% | 329% |
| Beta (5Y) | 1.37 | 0.77 |
| Employees | 246 | 132 |
| StockData Score | ||
| Total score | 8 | 12 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 3 | 4 (better) |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 49.1× (better) | 141× |
| P/S | 1.6× (better) | 33.2× |
| P/B | 0.9× (better) | 11.1× |
| EV/EBITDA | – | 143× |
| P/FCF | – | 71.8× |
| FCF yield | −40.6% | 1.4% (better) |
| Fair value | – | $36.28 |
| Margin of safety | – | −299% |
| Growth | ||
| Revenue growth (TTM) | −15.0% | 34.8% (better) |
| Revenue growth, 5Y average | 58.9% (better) | 10.0% |
| Net income growth (TTM) | – | 59.3% |
| EPS growth (TTM) | – | 47.1% |
| Profitability | ||
| Operating margin | −5.7% | 20.7% (better) |
| Net margin | 2.9% | 29.4% (better) |
| FCF margin | −65.9% | 46.3% (better) |
| Return on equity | 1.6% | 11.0% (better) |
| Return on invested capital | – | 73.3% |
| Financial health | ||
| Debt / equity | 0.00 (better) | 0.00 |
| Current ratio | 7.91 | 21.71 (better) |
| Altman Z-score | 1.01 | 128.91 (better) |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 86.0% | 117% |
| Held by insiders | 7.8% | 1.7% |
| Insider net buying, 12 months | −$1.2M (better) | −$86.9M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 8.9% | 14.7% |
Go deeper
- ARVN stock overview
- ARVN income statement
- ARVN valuation and score
- PTGX stock overview
- PTGX income statement
- PTGX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.